Cytogen to absorb Genome Care in small-scale merger

Cytogen said Wednesday it has decided to merge with its wholly owned subsidiary Genome Care through a small-scale absorption merger. The company plans to integrate Genome Care's reproductive genomics diagnosis business with Cytogen's circulating tumor cell-based precision medicine operations to create synergies.

Under the terms of the merger agreement signed on July 30, Genome Care will cease to exist as a separate legal entity while Cytogen remains the surviving company. The consolidation is scheduled to take effect on Oct. 1 without the issuance of new shares.

The merger is expected to improve operational efficiency by integrating research and development capabilities, inspection operating systems, sales networks and management resources, allowing the company to cut duplicate costs.

Genome Care reported revenue of 11 billion won ($7.67 million) for 2025, up from 8.3 billion won ($5.8 million) in the previous year, while operating profit rose to 2.95 billion won ($2.07 million) from 1.78 billion won ($1.24 million). Net income climbed to 2.69 billion won ($1.88 million) from 1.48 billion won ($1.03 million).

Genome Care specializes in providing prenatal and infertility diagnosis solutions, including non-invasive prenatal tests and pre-implantation genetic tests.